Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 16/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184409 | 0.85 | VCAM1 (0.60) | HCAR3KMT2AMAPT | |
| SCHEMBL1466985 | 0.84 | CDC25B (0.77) | HCAR3MEN1KMT2AMAPT | |
| SCHEMBL321911 | 0.83 | HCAR3 (1.00) | HCAR3MEN1KMT2ACASP6TSHR | |
| Hydrochloric Acid SCHEMBL321637 | 0.81 | HCAR3 (0.97) | HCAR3MEN1KMT2ACASP6TSHR | |
| SCHEMBL6044645 | 0.81 | HCAR3 (0.72) | HCAR3MEN1KMT2AMAPT | |
| SCHEMBL3613079 | 0.80 | HCAR3 (0.72) | HCAR3MEN1KMT2ACASP6TSHR | |
| SCHEMBL2426051 | 0.80 | HCAR3 (0.71) | HCAR3MEN1KMT2ACASP6TSHR | |
| SCHEMBL751533 | 0.79 | HCAR3 (0.62) | HCAR3MEN1KMT2AMAPT | |
| SCHEMBL4238591 | 0.79 | HCAR3 (1.00) | HCAR3MEN1KMT2ACASP6TSHR | |
| SCHEMBL24032 | 0.79 | HCAR3 (1.00) | HCAR3MEN1KMT2ACASP6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853368-B2 | Human antibodies against human glycoprotein VI and their use | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| US-20060088531-A1 | Human antibodies against human glycoprotein VI and their use | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885MEN1 4692/4885KMT2A 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.